youtube_live
Q3 2026 earnings • 8:00 AM tomorrow
See detailschevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$87.53
arrow_downward
-0.73%(-0.64) 1D
$87.53
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$88.20
High
$88.74
Low
$87.20
Mkt. cap
21.99B
Avg. vol.
1.05M
Volume
709.98K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.49
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$88.20
High
$88.74
Low
$87.20
Mkt. cap
21.99B
Avg. vol.
1.05M
Volume
709.98K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.49
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
10 hours ago
BioNTech earnings up next: Can revenue rebound offset cancer setback?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR